Mantis Biotech
Builds digital twins of humans using synthetic datasets for medicine, sports, and defense.
Website: https://mantisbiotech.com
Cover Block
| Field | Value |
|---|---|
| Name | Mantis Biotech |
| Tagline | Builds digital twins of humans using synthetic datasets for medicine, sports, and defense |
| Headquarters | San Francisco, California |
| Founded | 2025 |
| Stage | Seed |
| Business Model | B2B |
| Industry | Healthtech |
| Technology Type | Biotech / Life Sciences (synthetic data, AI) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding Label | Seed |
| Total Disclosed | ~$7.4M [The AI Insider, April 2026] |
Links
- Website: https://mantisbiotech.com/
- LinkedIn: https://www.linkedin.com/company/mantis-biotech
- Y Combinator profile: https://www.ycombinator.com/companies/mantis
- Crunchbase: https://www.crunchbase.com/organization/mantis-biotech
Executive Summary
Mantis Biotech is a San Francisco company building synthetic datasets that power digital twins of the human body, with target use cases spanning clinical trial design, sports performance, and defense [TechCrunch, March 2026]. The company emerged from Y Combinator and disclosed approximately $7.4M in seed funding in early 2026, with participation from Decibel VC, Liquid 2, StoryHouse Ventures, Pioneer Fund, and Spot VC [The AI Insider, April 2026]. It was founded in 2025 by Georgia Witchel, a 24-year-old former professional ice climber [Medium, March 2026]; [Startup Strides, 2026]. The technical premise is that disparate biomedical inputs can be combined into synthetic representations of anatomy, physiology, and behavior, addressing a persistent data-availability bottleneck in trial recruitment and biomedical device validation [TechCrunch, March 2026]; [Crunchbase, retrieved 2026]. The team remains small at three employees [Y Combinator, retrieved 2026]. Investor interest sits at the intersection of in-silico trial methods and generative methods in regulated, data-scarce verticals. Over the next 12 to 18 months, the watch items are first paying customers, the regulatory framing of any synthetic cohort outputs, and whether Mantis can convert YC and tier-one seed validation into a defensible data position.
Data Accuracy: GREEN -- Confirmed across TechCrunch, Y Combinator, Crunchbase, and The AI Insider.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | B2B |
| Industry / Vertical | Healthtech (with sports and defense adjacencies) |
| Technology Type | Synthetic data, AI-driven digital twins |
| Geography | North America (San Francisco) |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder (Georgia Witchel) |
| Funding | Seed, ~$7.4M disclosed |
How the Company Got Here
Mantis Biotech was founded in 2025 by Georgia Witchel and incorporated as a San Francisco-based company through the Y Combinator program [Y Combinator, retrieved 2026]. The company describes itself publicly as building digital twins of humans, with a near-term emphasis on biomedical research and a longer-term framing that extends to sports performance and defense applications [Medium, March 2026]. Crunchbase describes the company as building "a unified biomedical device testing and regulatory platform" [Crunchbase, retrieved 2026].
The principal milestone to date is the company's seed financing, which was reported at approximately $7.4M and announced in early 2026 [The AI Insider, April 2026]; [Fyself News, retrieved 2026]; [Yahoo Tech, retrieved 2026]. Press coverage in late March 2026 by TechCrunch provided the first detailed third-party description of the product approach [TechCrunch, March 2026]. The company reports a headcount of three employees [Y Combinator, retrieved 2026].
Founder Georgia Witchel has spoken publicly about an unconventional path into the company, including a prior career in professional ice climbing [Startup Strides, 2026]. Authority Magazine's interview placed her at 24 years old at the time of the seed round [Medium, March 2026].
Data Accuracy: GREEN -- Confirmed by Y Combinator, Crunchbase, TechCrunch, and Medium.
Product and Technology
Mantis's stated product is a synthetic data engine that combines disparate biomedical inputs into digital twins representing human anatomy, physiology, and behavior [TechCrunch, March 2026]. The intended customers are organizations that need access to richer biomedical cohorts than they can practically collect, with a near-term wedge in biomedical device testing and regulatory workflows [Crunchbase, retrieved 2026]. Mantis's own framing in interviews extends beyond healthcare to sports performance modeling and defense applications [Medium, March 2026].
The technical approach treats the digital twin as a synthetic dataset object that downstream researchers can sample from, condition on, or use to augment under-powered real-world cohorts [TechCrunch, March 2026]. The company has not publicly disclosed which model architectures, data partnerships, or validation methodologies underpin the system.
Founder interviews have flagged the ethical perimeter of predictive synthetic data as an active area of internal work [Medium, March 2026].
Data Accuracy: YELLOW -- Product framing confirmed by TechCrunch, Medium, and Crunchbase, but underlying architecture and validation evidence are not publicly documented.
Market Research and Opportunity
The market backdrop for Mantis is a clinical research system where synthetic and in-silico methods are increasingly being treated as legitimate trial-design tools. According to coverage of Mantis's launch, roughly 80% of clinical trials are reported to experience delays attributable to data inaccuracies, with each delayed trial costing approximately $15M [Prism News, retrieved 2026].
| Sizing claim | Value |
|---|---|
| Share of clinical trials delayed by data inaccuracies | ~80% |
| Reported cost per delayed trial | ~$15M |
The demand drivers Mantis is positioned against include shrinking patient recruitment funnels, growing regulator openness to in-silico evidence in device submissions, and cost pressure on biopharma R&D budgets [Crunchbase, retrieved 2026]; [TechCrunch, March 2026]. The sports and defense extensions Mantis describes are adjacent markets where human-performance modeling is an active procurement category [Medium, March 2026].
The most relevant regulatory force is the trajectory of FDA and EMA guidance on synthetic control arms and computational modeling in device submissions. The countervailing macro force is the scrutiny of training data provenance, bias, and reproducibility.
Data Accuracy: YELLOW -- Single-source sizing claim corroborated by category-level press but not by a named third-party market report.
Competitive Landscape
Mantis is entering a category that already has a well-funded, late-stage reference player in Unlearn.AI.
| Company | Positioning | Stage / Funding |
|---|---|---|
| Mantis Biotech | Synthetic datasets and digital twins for medicine, sports, defense | Seed, ~$7.4M |
| Unlearn.AI | Digital twins of trial participants for control-arm augmentation | Later-stage, multi-round venture-backed |
Segment by segment, the competitive map breaks into three groups: dedicated in-silico trial vendors led by Unlearn.AI; large biomedical simulation incumbents (Dassault's Living Heart program, Sim&Cure); and a wave of generative-AI-for-biology startups.
Mantis's defensible edges today are capital and validation: a $7.4M seed with named institutional participants and a YC stamp [The AI Insider, April 2026]; [Y Combinator, retrieved 2026]. The cross-vertical framing is a positioning edge in fundraising conversations. The most exposed flanks are evidentiary and commercial. Unlearn.AI's specific advantage is a multi-year head start on the statistical and regulatory work that pharma sponsors require.
Data Accuracy: YELLOW -- Competitor identity confirmed by TechCrunch; relative stage and customer detail inferred from public reporting.
Opportunity
If Mantis executes on its stated thesis, the prize is to become the default synthetic-data layer for human biology across regulated industries.
Growth scenarios.
| Scenario | What happens | Catalyst |
|---|---|---|
| Become the default synthetic cohort provider for medical device submissions | Mantis wins reference deployments with two to three mid-cap device manufacturers | A named device-manufacturer partnership in 2026 or 2027 |
| Win a defense human-performance contract | A DoD-adjacent buyer procures Mantis digital twins for warfighter performance modeling | A SBIR or prime contractor partnership |
| Cross-license synthetic cohorts to pharma | Mantis sells synthetic augmentation data to sponsors running underpowered Phase II trials | A named pharma pilot |
The size of the win. The most useful comparable is Unlearn.AI. If Mantis reaches a similar position in device testing rather than pharma controls, a comparable later-stage valuation is a reasonable scenario. The broader prize is regulated biomedical simulation, in-silico trial methods, and human-performance modeling.
Data Accuracy: YELLOW -- Scenarios grounded in cited press and category comparables; specific outcomes are explicitly framed as scenarios rather than forecasts.
Sources
- [TechCrunch, March 2026] Mantis Biotech is making 'digital twins' of humans to help solve medicine's data availability problem | https://techcrunch.com/2026/03/30/mantis-biotech-is-making-digital-twins-of-humans-to-help-solve-medicines-data-availability-problem/
- [Medium, March 2026] Mantis Biotech CEO Georgia Witchel on Building Digital Twins, the Ethics of Predictive Data and Why Startup Founders "Are Not Special" | https://medium.com/authority-magazine/mantis-biotech-ceo-georgia-witchel-on-building-digital-twins-the-ethics-of-predictive-data-and-why-c14f46268b44
- [Y Combinator, retrieved 2026] Mantis: Digital Twins of humans | https://www.ycombinator.com/companies/mantis
- [Crunchbase, retrieved 2026] Mantis biotech - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/mantis-biotech
- [Startup Strides, 2026] Ep 58: From Ice Climbing to Startups: Georgia Witchel's Unconventional Founder Path | https://open.spotify.com/episode/3iRiRfIVczNg6nL1Yhqven
- [Prism News, retrieved 2026] Mantis Biotech Builds Digital Twins of Humans to Solve Medicine's Data Problem | https://www.prismnews.com/news/mantis-biotech-builds-digital-twins-of-humans-to-solve
- [Fyself News, retrieved 2026] Mantis Biotech is creating a digital twin of humans to help solve medical data availability issues | https://news.fyself.com/mantis-biotech-is-creating-a-digital-twin-of-humans-to-help-solve-medical-data-availability-issues/
- [The Indian Practitioner, retrieved 2026] Mantis Biotech Uses AI-Powered Digital Twins to Transform Biomedical Research | https://theindianpractitioner.com/mantis-biotech-uses-ai-powered-digital-twins-to-transform-biomedical-research/
- [Yahoo Tech, retrieved 2026] Mantis Biotech is making 'digital twins' of humans to help solve medicine's data availability problem | https://tech.yahoo.com/ai/meta-ai/articles/mantis-biotech-making-digital-twins-143000600.html
- [The AI Insider, April 2026] Mantis Biotech Announces $7.4M in Funding to Advance AI-Driven Digital Twin Models for Biomedical Research | https://theaiinsider.tech/2026/04/02/mantis-biotech-announces-7-4-million-in-funding-to-advance-ai-driven-digital-twin-models-for-biomedical-research/
- [Mantis Biotech, retrieved 2026] Mantis | https://mantisbiotech.com/
- [LinkedIn, retrieved 2026] Mantis Biotech company page | https://www.linkedin.com/company/mantis-biotech
Articles about Mantis Biotech
- Mantis Biotech Wants a Synthetic Stand-In for Every Patient a Trial Cannot Recruit — The Y Combinator-backed startup is building digital twins of human anatomy and physiology, with $7.4M in seed funding and a tough regulatory road ahead.